Loading stock data…
Utah Medical Products, Inc. (UTMD)
$69.16-1.94 (-2.73%)
Market ClosedLast close Sep 8
Utah Medical Products, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Utah Medical Products, Inc. in the Healthcare sector is trading at $69.16 with a market capitalization of $220M. The stock is currently 9% below its 52-week high of $75.75, remaining 7.1% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 35) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $8.72M↓ | $9.04M↓ | $9.81M↓ | $9.95M |
| Gross Profit | — | $5.28M↑ | $5.26M↓ | $5.60M↑ | $5.59M |
| Operating Income | — | $3.01M↑ | $2.44M↓ | $2.61M↓ | $3.20M |
| Net Income | — | $2.60M↑ | $2.57M↓ | $2.63M↓ | $3.05M |
Peer Comparison
JNJUNHPFE
Fundamentals
Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HO...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$220.19M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.09
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.79%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.59%
Volume
Today's trading volume
28,028
Recent News
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
UTMD's Q2 earnings per share decline 10.1% year over year, while quarterly revenues face pressure from lost customers and slower new business growth.
The Zacks Analyst Blog Highlights Berkshire, Eli Lilly, Walmart, Universal Health Realty Income and Utah
BRK.B, LLY and WMT headline top analyst reports, highlighting business strengths, growth drivers and key risks shaping their outlooks.
Top Analyst Reports for Berkshire Hathaway, Eli Lilly & Walmart
Berkshire Hathaway, Eli Lilly and Walmart headline new analyst reports, highlighting growth drivers, opportunities and key risks shaping their outlooks.
Utah Medical's Q1 Earnings Fall Y/Y Due to Elevated Litigation Costs
UTMD reports a year-over-year decline in Q1 earnings per share and sales, pressured by lost distributor business and higher costs, despite improved margins and a strong balance sheet.
Utah Medical Gains 32% in a Year: Should You Buy the Stock?
UTMD's niche leadership, global footprint, and strong cash generation position it to benefit from rising demand for high-quality maternal and neonatal healthcare solutions.